Affinity maturation of an anti-V antigen IgG expressed in situ through adenovirus gene delivery confers enhanced protection against Yersinia pestis challenge

Gene Therapy

Volumn 17, Issue 7, 2010, Pages 913-921

  Van Blarcom, T J ^a   Sofer Podesta, C ^b   Ang, J ^b   Boyer, J L ^b   Crystal, R G ^b   Georgiou, G ^a,c  

^a UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c The University of Texas at Austin   (United States)

Author keywords

adenovirus gene transfer; affinity maturation; antibody; protection; Yersinia pestis

Indexed keywords

ADENOVIRUS VECTOR; BACTERIAL ANTIGEN; BACTERIUM ANTIBODY; IMMUNOGLOBULIN G2B MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG; LCRV PROTEIN, YERSINIA; NEUTRALIZING ANTIBODY; PORE FORMING CYTOTOXIC PROTEIN;

ANIMAL EXPERIMENT; ANTIBODY AFFINITY; ANTIBODY TITER; ARTICLE; BACTERIAL IMMUNITY; CONTROLLED STUDY; CYTOPLASM; DISSOCIATION CONSTANT; ESCHERICHIA COLI; FLOW CYTOMETRY; GENE ISOLATION; GENETIC CODE; GENETIC IMMUNIZATION; GENETIC VARIABILITY; HUMAN ADENOVIRUS 5; LD 50; MALE; MOUSE; MUTAGENESIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROVOCATION TEST; SURFACE PLASMON RESONANCE; SURVIVAL; VIRAL GENE THERAPY; YERSINIA PESTIS; ANIMAL; BAGG ALBINO MOUSE; C57BL MOUSE; EVALUATION STUDY; GENE THERAPY; GENE TRANSFER; GENE VECTOR; GENETICS; HUMAN; HUMAN ADENOVIRUS; IMMUNOLOGY; MORTALITY; PASSIVE IMMUNIZATION; PLAGUE; PROCEDURES;

ADENOVIRUSES, HUMAN; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; ANTIBODY AFFINITY; ANTIGENS, BACTERIAL; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HUMANS; IMMUNIZATION, PASSIVE; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; PLAGUE; PORE FORMING CYTOTOXIC PROTEINS; YERSINIA PESTIS; GENETIC THERAPY;

ADENOVIRIDAE; BACTERIA (MICROORGANISMS); ESCHERICHIA COLI; HUMAN ADENOVIRUS; MUS; YERSINIA PESTIS;

EID: 77954537924     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2010.42     Document Type: Article

References (40)

1. Sofer-Podesta C, Ang J, Hackett NR, Senina S, Perlin D, Crystal RG et al. Adenovirus-mediated delivery of an anti-V antigen monoclonal antibody protects mice against a lethal Yersinia pestis challenge. Infect Immun 2009; 77: 1561-1568.
2. Smiley ST. Immune defense against pneumonic plague. Immunol Rev 2008; 225: 256-271.
3. Brouqui P, Raoult D. Arthropod-borne diseases in homeless. Ann N Y Acad Sci 2006; 1078: 223-235.
4. Zhou D, Han Y, Yang R. Molecular and physiological insights into plague transmission, virulence and etiology. Microbes Infect 2006; 8: 273-284.
5. Hill J, Eyles JE, Elvin SJ, Healey GD, Lukaszewski RA, Titball RW et al. Administration of antibody to the lung protects mice against pneumonic plague. Infect Immun 2006; 74: 3068-3070.
6. Hill J, Copse C, Leary S, Stagg AJ, Williamson ED, Titball RW et al. Synergistic protection of mice against plague with monoclonal antibodies specific for the F1 and V antigens of Yersinia pestis. Infect Immun 2003; 71: 2234-2238.
7. Hill J, Leary SE, Griffin KF, Williamson ED, Titball RW. Regions of Yersinia pestis V antigen that contribute to protection against plague identified by passive and active immunization. Infect Immun 1997; 65: 4476-4482.
8. Maynard JA, Maassen CB, Leppla SH, Brasky K, Patterson JL, Iverson BL et al. Protection against anthrax toxin by recombinant antibody fragments correlates with antigen affinity. Nat Biotech-nol 2002; 20: 597-601.
9. Wu H, Pfarr DS, Johnson S, Brewah YA, Woods RM, Patel NK et al. Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract. J Mol Biol 2007; 368: 652-665.
10. Marks JD. Deciphering antibody properties that lead to potent botulinum neurotoxin neutralization. Mov Disord 2004; 19 (Suppl 8): S101-S108.
11. Barbas 3rd CF, Hu D, Dunlop N, Sawyer L, Cababa D, Hendry RM et al. In vitro evolution of a neutralizing human antibody to human immunodeficiency virus type 1 to enhance affinity and broaden strain cross-reactivity. Proc Natl Acad Sci USA 1994; 91: 3809-3813.
12. Mabry R, Rani M, Geiger R, Hubbard GB, Carrion Jr R, Brasky K et al. Passive protection against anthrax by using a high-affinity antitoxin antibody fragment lacking an Fc region. Infect Immun 2005; 73: 8362-8368.
13. Riaño-Umbarila L, Juárez-González VR, Olamendi-Portugal T, Ort́iz-León M, Possani LD, Becerril B et al. A strategy for the generation of specific human antibodies by directed evolution and phage display. An example of a single-chain antibody fragment that neutralizes a major component of scorpion venom. FEBS J 2005; 272: 2591-2601.
14. Rajpal A, Beyaz N, Haber L, Cappuccilli G, Yee H, Bhatt RR et al. A general method for greatly improving the affinity of antibodies by using combinatorial libraries. Proc Natl Acad Sci USA 2005; 102: 8466-8471.
15. Harvey BR, Georgiou G, Hayhurst A, Jeong KJ, Iverson BL, Rogers GK et al. Anchored periplasmic expression, a versatile technology for the isolation of high-affinity antibodies from Escherichia coli-expressed libraries. Proc Natl Acad Sci USA 2004; 101: 9193-9198.
16. Hayhurst A, Happe S, Mabry R, Koch Z, Iverson BL, Georgiou G et al. Isolation and expression of recombinant antibody fragments to the biological warfare pathogen Brucella melitensis. J Immunol Methods 2003; 276: 185-196.
17. Hayhurst A. Improved expression characteristics of single-chain Fv fragments when fused downstream of the Escherichia coli maltose-binding protein or upstream of a single immuno-globulin-constant domain. Protein Expr Purif 2000; 18: 1-10.
18. Martin AC. Accessing the Kabat antibody sequence database by computer. Proteins 1996; 25: 130-133.
19. Foote J, Eisen HN. Kinetic and affinity limits on antibodies produced during immune responses. Proc Natl Acad Sci USA 1995; 92: 1254-1256.
20. Mohamed N, Clagett M, Li J, Jones S, Pincus S, D'Alia G et al. A high-affinity monoclonal antibody to anthrax protective antigen passively protects rabbits before and after aerosolized Bacillus anthracis spore challenge. Infect Immun 2005; 73: 795-802.
21. Fang J, Qian JJ, Yi S, Harding TC, Tu GH, VanRoey M et al. Stable antibody expression at therapeutic levels using the 2A peptide. Nat Biotechnol 2005; 23: 584-590.
22. Jiang M, Shi W, Zhang Q, Wang X, Guo M, Cui Z et al. Gene therapy using adenovirus-mediated full-length anti-HER-2 antibody for HER-2 overexpression cancers. Clin Cancer Res 2006; 12: 6179-6185.
23. BenAmmar-Ceccoli S, Humblot S, Crouzier R, Acres B, Kieny MP, Herlyn D et al. Recombinant vaccinia viruses expressing immunoglobulin variable regions efficiently and selectively protect mice against tumoral B-cell growth. Cancer Gene Ther 2001; 8: 815-826.
24. Daugherty AL, Mrsny RJ. Formulation and delivery issues for monoclonal antibody therapeutics. Adv Drug Deliv Rev 2006; 58: 686-706.
25. Samaranayake H, Wirth T, Schenkwein D, Räty JK, Ylä-Herttuala S. Challenges in monoclonal antibody-based therapies. Ann Med 2009; 41: 322-331.
26. Chung CH. Managing premedications and the risk for reactions to infusional monoclonal antibody therapy. Oncologist 2008; 13: 725-732.
27. Joshi A, Bauer R, Kuebler P, White M, Leddy C, Compton P et al. An overview of the pharmacokinetics and pharmacodynamics of efalizumab: a monoclonal antibody approved for use in psoriasis. J Clin Pharmacol 2006; 46: 10-20.
28. Boyer JL, Kobinger G, Wilson JM, Crystal RG. Adenovirus-based genetic vaccines for biodefense. Hum Gene Ther 2005; 16: 157-168.
29. De BP, Hackett NR, Crystal RG, Boyer JL. Rapid/sustained anti-anthrax passive immunity mediated by co-administration of Ad/AAV. Mol Ther 2008; 16: 203-209.
30. Hashimoto M, Boyer JL, Hackett NR, Wilson JM, Crystal RG. Induction of protective immunity to anthrax lethal toxin with a nonhuman primate adenovirus-based vaccine in the presence of preexisting anti-human adenovirus immunity. Infect Immun 2005; 73: 6885-6891.
31. Lazar GA, Dang W, Karki S, Vafa O, Peng JS, Hyun L et al. Engineered antibody Fc variants with enhanced effector function. Proc Natl Acad Sci USA 2006; 103: 4005-4010.
32. Chiuchiolo MJ, Boyer JL, Krause A, Senina S, Hackett NR, Crystal RG et al. Protective immunity against respiratory tract challenge with Yersinia pestis in mice immunized with an adenovirus-based vaccine vector expressing V antigen. J Infect Dis 2006; 194: 1249-1257.
33. Chen G, Hayhurst A, Thomas JG, Harvey BR, Iverson BL, Georgiou G et al. Isolation of high-affinity ligand-binding proteins by periplasmic expression with cytometric screening (PECS). Nat Biotechnol 2001; 19: 537-542.
34. Mazor Y, Van Blarcom T, Iverson BL, Georgiou G. E-clonal antibodies: selection of full-length IgG antibodies using bacterial periplasmic display. Nat Protoc 2008; 3: 1766-1777.
35. Ribnicky B, Van Blarcom T, Georgiou G. A scFv antibody mutant isolated in a genetic screen for improved export via the twin arginine transporter pathway exhibits faster folding. J Mol Biol 2007; 369: 631-639.
36. Fromant M, Blanquet S, Plateau P. Direct random mutagenesis of gene-sized DNA fragments using polymerase chain reaction. Anal Biochem 1995; 224: 347-353.
37. Myszka DG. Improving biosensor analysis. J Mol Recognit 1999; 12: 279-284.
38. Rosenfeld MA, Yoshimura K, Trapnell BC, Yoneyama K, Rosenthal ER, Dalemans W et al. In vivo transfer of the human cystic fibrosis transmembrane conductance regulator gene to the airway epithelium. Cell 1992; 68: 143-155.
39. Mittereder N, March KL, Trapnell BC. Evaluation of the concentration and bioactivity of adenovirus vectors for gene therapy. J Virol 1996; 70: 7498-7509.
40. Wu H, Pfarr DS, Tang Y, An LL, Patel NK, Watkins JD et al. Ultra-potent antibodies against respiratory syncytial virus: effects of binding kinetics and binding valence on viral neutralization. J Mol Biol 2005; 350: 126-144.